Psychedelic Stock News

The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?

We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.

TSI EDITOR | 2021-09-20

AdvisorShares Launches Psychedelics ETF (Ticker: PSIL)

AdvisorShares' new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol "PSIL") with a focus on small-cap psychedelic stocks.

TSI EDITOR | 2021-09-16

The Two-Pronged Psychedelics Solution To The Opioid Crisis

Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.

TSI EDITOR | 2021-09-16

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Compass Pathways acquires an unspecified IP portfolio of psychedelic and emphathogenic substances.

TSI EDITOR | 2021-09-15

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.

TSI EDITOR | 2021-09-14

Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression

Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.

TSI EDITOR | 09/14/2021

Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids

Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.

TSI EDITOR | 2021-09-13

atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.

TSI EDITOR | 2021-09-10

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.

TSI EDITOR | 2021-09-10

Wesana Health Announces Closing of PsyTech Acquisition

Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.

TSI EDITOR | 2021-09-09